Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France.
The metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France was determined using a neonatal mouse model and compared with the outcome in patients after standard metronidazole therapy (0.75 g/day for 5 days). All isolates found to be clinically resistant to metronidazole (4/11) exhibited an ID50 > 120 mg/kg in the mouse model. This therefore appears to be a suitable animal model in which to explore drug failures in human giardiasis.
Lemée
V
V
Laboratoire de Parasitologie Expérimentale, CHU Charles-Nicolle, 76031 Rouen Cedex, France. llemee1234@aol.com
Zaharia
I
I
Nevez
G
G
Rabodonirina
M
M
Brasseur
P
P
Ballet
J J
JJ
Favennec
L
L
D015766:Albendazole / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000831:Animals, Newborn; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005243:Feces / Q000469:parasitology*; D005849:Gerbillinae; D016829:Giardia lamblia / Q000187:drug effects*; D005873:Giardiasis / Q000188:drug therapy; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice
D000890:Anti-Infective Agents; D000981:Antiprotozoal Agents; D008795:Metronidazole; D015766:Albendazole